Thus, further study is needed to address the regulatory network between FGF9 and β‐catenin, which could be important for the carcinogenic signaling involved in NASH‐driven HCC initiation and progression. The gene discussed is FGF9; the disease is metabolic dysfunction-associated steatohepatitis.